14 November 2023 - Sotatercept added to background therapy appears to improve clinical outcomes, but there are uncertainties on long ...
14 November 2023 - The utilisation analysis public release documents from the June 2023 DUSC meeting are now available. ...
13 November 2023 - The Outcome Statement from the September 2023 DUSC meeting is now available. ...
10 November 2023 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2023 ...
9 November 2023 - Two more documents are now available. ...
30 October 2023 - Independent appraisal committee voted that across all patient sub-populations, arsa-cel demonstrated a net health benefit when ...
27 October 2023 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2023 PBAC ...
25 September 2023 - Registration now open for 5 October “Early Insights” webinar. ...
14 September 2023 - Using weighted analyses across all patient subpopulations, atidarsagene autotemcel would achieve common thresholds for cost effectiveness if priced ...
28 August 2023 - The final report of the Efficient Funding of Chemotherapy Review is now available. ...
25 August 2023 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2023 PBAC ...
26 July 2023 - Registration now open for 3 August “Early Insights” webinar. ...
20 July 2023 - The utilisation analysis public release documents from the February 2023 DUSC meeting are now available. ...
14 July 2023 - The public summary documents (first time decisions not to recommend and deferrals) from the March 2023 PBAC ...
30 June 2023 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the March 2023 PBAC ...